Calliditas Therapeutics, a specialty pharmaceutical company, completed the acquisition of a 62.7% stake in Genkyotex, a biopharmaceutical company in NOX therapies, for €88m ($104m). "We look forward to leveraging our strong late stage clinical team, CMC and regulatory expertise as well as our learnings from our Phase 3 Nefecon program to navigate and execute an efficient path forward for setanaxib. We continue to deliver on our strategy focusing on adding late stage assets with an orphan focus and encouraging data in patients to build a company focused on delivering solution for patients with diseases with high unmet needs," Renée Aguiar-Lucander, Calliditas CEO.